EVALUASI EFEKTIVITAS PENGGUNAAN OBAT ANTIEMETIK DAN RESPON MUAL MUNTAH PADA PENDERITA KANKER PAYUDARA YANG MENJALANI KEMOTERAPI DI RSUD PROF. Dr. MARGONO SOEKARDJO

ALFAROZY, AZKALIA RIZQI (2015) EVALUASI EFEKTIVITAS PENGGUNAAN OBAT ANTIEMETIK DAN RESPON MUAL MUNTAH PADA PENDERITA KANKER PAYUDARA YANG MENJALANI KEMOTERAPI DI RSUD PROF. Dr. MARGONO SOEKARDJO. Bachelor thesis, UNIVERSITAS MUHAMMADIYAH PURWOKERTO.

[img]
Preview
Text
AZKALIA RISQI ALFAROZY COVER.pdf

Download (1MB) | Preview
[img]
Preview
Text
AZKALIA RISQI ALFAROZY BAB I.pdf

Download (718kB) | Preview
[img]
Preview
Text
AZKALIA RISQI ALFAROZY BAB II.pdf

Download (736kB) | Preview
[img] Text
AZKALIA RISQI ALFAROZY BAB III.pdf
Restricted to Repository staff only

Download (841kB)
[img] Text
AZKALIA RISQI ALFAROZY BAB IV.pdf
Restricted to Repository staff only

Download (789kB)
[img] Text
AZKALIA RISQI ALFAROZY BAB V.pdf
Restricted to Repository staff only

Download (591kB)
[img]
Preview
Text
AZKALIA RISQI ALFAROZY DAFTAR PUSTAKA.pdf

Download (718kB) | Preview
[img] Text
AZKALIA RISQI ALFAROZY LAMPIRAN.pdf
Restricted to Repository staff only

Download (1MB)

Abstract

Azkalia Rizqi Alfarozy, Evaluation of effectiveness of antiemetics drugs and nausea vomiting response in breast cancer patients undergoing chemotherapy in Prof. Dr. Margono Soekardjo hospital in Purwokerto. Advisor : Susanti, M.Phil., Apt and Wahyu Utaminingrum, M.Sc., Apt Antiemetics commonly use to control nausea and vomiting in patients who receive chemotherapy agents. The emetogenicity of chemotherapy agents and antiemetic protocol given to patient can contribute to the experience of nausea and vomiting. This study aimed to determine the effectiveness of antiemetic drugs used by breast cancer patients and to compare the risk factors of chemotherapyinduced nausea and vomiting. This observational study with cross sectional design was conducted in Prof Dr. Margono Soekardjo hospital, Purwokerto. Patient included in this study were breast cancer patients who received any chemotherapy protocol from December 2014 to April 2015 and consented to participate. Patients were required to record episodes of nausea and vomiting in checklist sheet in 24 hours to day 5 after chemotherapy administered. The chemotherapy protocol were stratified into high and low emetogenicity groups and the episodes of nausea and vomiting in acute and delayed phase were measured using National Cancer Institute-Common Toxicity Criteria (NCI-CTC). In this study, there were 47 patients who met the inclusion criterias, 46 patients received Highly Emetogenic Chemotherapy (HEC) and one patient received Low Emetogenic Chemotherapy (LEC). All patients received premedication of antiemetic combination: dexamethasone, ondansetron and ranitidine, and postmedication antiemetic of metoclorpramid or ondansetron. The antiemetics used in patients who received the HEC, were reported to be effective to control nausea in acute phase (24 hours) in 89,13% patients and 50% patients in delayed phase days (2-5). Moreover, this regimen was effective to control vomiting in acute phase in 78,26% patients and 52,17% patients in delayed phase. However, the antiemetics regimen given to the patient who received the LEC, was reported to be effective to control nausea and vomiting either in acute and delayed phase in 100% patients. Younger patients (62,5%) were reported to experience more nausea in acute phase than older patients (37,5%). Patients in 1-3 cycle of chemotherapy has showed 0,2 times higher probability of experiencing the vomiting in acute and delayed phase. Futhermore, the probability of nausea in patients with history of motion sickness was 5 times higher than patients without history of motion sickness. Overall, the results of this study showed that antiemetic protocol used in Prof. Dr. Margono Soekardjo hospital was 100 % effective for controlling nausea and vomiting in patients who received LEC. However, antiemetics used in patients received HEC were showed to be less effective to treat nausea and vomiting in acute and delayed phase. The factors that contributed to the presence of nausea vomiting in acute phase were history of motion sickness (p=0,040) and cycle of chemotherapy (p=0.028) and the presence of vomiting in delayed phase phase is cycle of chemotherapy (p=0.045).

Item Type: Thesis (Bachelor)
Additional Information: Pembimbing: Susanti, M.Phill. dan Wahyu Utaminigrum, M.Sc., Apt.
Uncontrolled Keywords: effectiveness, breast cancer, antiemetic
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Fakultas Farmasi > Farmasi
Depositing User: Nur Hardiansyah
Date Deposited: 08 Aug 2017 02:45
Last Modified: 08 Aug 2017 02:45
URI: http://repository.ump.ac.id/id/eprint/3196

Actions (login required)

View Item View Item